Leadiant FDA Tuesday, July 22, 1969 -0.80 Negative

FDA Approves MATULANE — Leadiant Biosciences, Inc.

Leadiant Biosciences, Inc. has secured FDA approval to manufacture a generic version of Procarbazine Hydrochloride, enabling the long-standing MATULANE indication to generate generic competition. This development is poised to destabilize the branded market by introducing a lower-cost alternative and a new entrant for a chemotherapy regimen with an establishing approval date.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed